Robert A Baiocchi MD, PhD


​ 

Robert A Baiocchi MD, PhD
Assoc ProfessorCollege of Medicinebaiocchi.1@osu.edu
B404 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-685-56667Fax: 614-292-3312
  • Viral Oncology

General Research Interest

HIV/AIDS and immune deficiency associated malignancies, Experimental therapeutics of lymphoma, Viral oncogenesis

Research Description

Our laboratory program focuses on 3 major areas of research: (1) experimental therapeutics of lymphomas (epigenetics, antibodies, vaccine/immunotherapy); (2) mechanisms of Epstein-Barr virus driven B cell transformation; and (3) clinical research involving new methods to treat immune deficient patients (HIV/AIDS, post transplantation) who develop cancer.

Transinstitutional Work

Our trans-institutional collaborative work involves our participation in the National Cancer Institutes' AIDS Malignancy Consortium (AMC) and the Blood and Bone Marrow Transplantation Clinical Trials Network (BMT CTN).  As the institutional principal investigator of the AMC at Ohio State, i help develop new treatment protocols and manage patients with HIV/AIDS associated cancers.  I am part of a working group at the BMT-CTN developing clinical trials to perform autologous and allogeneic stem cell transplantation in HIV+ patients with refractory or relapsed lymphomas.

Current Publications

  • Baiocchi RAGenetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma.Cancer Res 74 1752-65 3/15/2014
  • Blum KAComplete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.Cancer 2/27/2014
  • Chung J, Karkhanis V, Tae S, Yan F, Smith P, Ayers LW, Agostinelli C, Pileri S, Denis GV, Baiocchi RA, Sif SProtein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.J Biol Chem 288 35534-47 12/6/2013
  • Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JMCyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.Leuk Res 37(10) 1195-9 10/1/2013
  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant 48(9) 1212-7 9/1/2013
  • Jones JA, Rupert AS, Poi M, Phelps MA, Andritsos L, Baiocchi R, Benson DM, Blum KA, Christian B, Flynn J, Penza S, Porcu P, Grever MR, Byrd JCFlavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Am J Hematol in press 8/20/2013
  • Alinari L, Pant S, McNamara K, Kalmar JR, Marsh W, Allen CM, Baiocchi RALymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male.Head Neck Pathol 6(4) 496-501 12/1/2012
  • Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn D, Baiocchi R, Grever MR, Lucas DMDual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.Clin Cancer Res 18(17) 4600-11 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu